The rationale for their combination comes from the evidence that antiangiogenic mechanisms may increase tumor hypoxia, leading to the upregulation of the costimulatory molecule OX40 in T-cell-mediated immunity; OX40 promotes the survival and expansion of CD8+T cells and the recall response of CD8+memory T cells [65]. The gene discussed is TNFRSF4; the disease is neoplasm.